1. Home
  2. Directory
  3. Nebraska
  4. Omaha
  5. Surgery
  6. NPI Profile
  7. Prescriptions 1215911813

SCOTT P. WATTENHOFER M.D.
Prescription History 1215911813
Surgery - Vascular Surgery in Omaha, NE

NPI Status: Active since December 06, 2005

Contact Information

515 N 162ND AVE
SUITE 300
OMAHA, NE
ZIP 68118
Phone: (402) 393-6624
Fax: (402) 393-6635

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SCOTT P. WATTENHOFER M.D., an active Vascular Surgery specialist practicing in Omaha, NE. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 227 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 94 claims alone.

Medication Index

C
E
G
H
X
No matching medications currently found on file.

Clopidogrel

Generic Formulation: Clopidogrel BisulfateSpecialty: Vascular Surgery
Provider Metrics Summary
Total Claims 59
30-Day Fills 94.3
Days Supply 2,814
NE State Average Benchmarks
Peer Average Claims56.0
Peer Average 30-Day Fills108.6
Peer Average Days Supply3,186
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $754.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.78

State Avg Cost Per Claim

$15.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.

Therapeutic Applications

Clopidogrel is used to prevent heart attacks and strokes in persons with heart disease (recent heart attack), recent stroke, or blood circulation disease (peripheral vascular disease). It is also used with aspirin to treat new/worsening chest pain (new heart attack, unstable angina) and to keep blood vessels open and prevent blood clots after certain procedures (such as cardiac stent). Clopidogrel works by blocking platelets from sticking together and prevents them from forming harmful clots. It is an antiplatelet drug. It helps keep blood flowing smoothly in your body.

Eliquis

Generic Formulation: ApixabanSpecialty: Vascular Surgery
Provider Metrics Summary
Total Claims 94
30-Day Fills 94.8
Days Supply 2,652
NE State Average Benchmarks
Peer Average Claims80.0
Peer Average 30-Day Fills108.9
Peer Average Days Supply2,987
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $53,230.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$566.29

State Avg Cost Per Claim

$690.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Gabapentin

Generic Formulation: GabapentinSpecialty: Vascular Surgery
Provider Metrics Summary
Total Claims 30
30-Day Fills 37.0
Days Supply 1,094
NE State Average Benchmarks
Peer Average Claims87.0
Peer Average 30-Day Fills129.3
Peer Average Days Supply3,730
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.5% less volume than the regional standard for practitioners inside NE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $546.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.21

State Avg Cost Per Claim

$22.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Hydrocodone-Acetaminophen

Generic Formulation: Hydrocodone/AcetaminophenSpecialty: Vascular Surgery
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 66
NE State Average Benchmarks
Peer Average Claims58.0
Peer Average 30-Day Fills59.0
Peer Average Days Supply1,072
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.2% less volume than the regional standard for practitioners inside NE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $136.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.16

State Avg Cost Per Claim

$22.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to relieve moderate to severe pain. It contains an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen). Hydrocodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Vascular Surgery
Provider Metrics Summary
Total Claims 25
30-Day Fills 46.0
Days Supply 1,316
NE State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills70.8
Peer Average Days Supply1,983
Conservative Utilization

This provider writes prescriptions for this formulation 49.0% less frequently than the standard regional baseline metric for practitioners inside NE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $25,358.06 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,014.32

State Avg Cost Per Claim

$735.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SCOTT P. WATTENHOFER M.D. provides transparency into local medical care patterns within Omaha, NE.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Vascular Surgery** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.